Related Experiment Video
Updated: Jun 2, 2026
Coronary Angiography During Ex-Situ Heart Perfusion in a Porcine Model
Published on: July 12, 2024
Clinical experience in the use of marginal donor hearts
Ai-ni Xie1, Nian-guo Dong, Kai-lun Zhang
1Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Insights
Using marginal donor hearts for heart transplantation offers a 100% 1-year survival rate, similar to standard donors. However, marginal donor hearts increase early complications and post-ICU stay, requiring careful patient selection and perioperative care.
Area of Science:
- Cardiology
- Transplantation Medicine
- Surgical Outcomes
Background:
- Heart transplantation is a standard therapy for end-stage heart disease.
- Limited studies exist on outcomes using marginal donor hearts.
- This study evaluates clinical outcomes of marginal donor heart transplants.
Purpose of the Study:
- To compare the clinical outcomes of heart transplantation using marginal versus standard donor hearts.
- To assess mortality and perioperative complications in both groups.
- To determine the viability and risks associated with marginal donor heart utilization.
Main Methods:
- Analysis of 21 orthotopic heart transplantations between September 2008 and July 2010.
- Comparison of six marginal donor hearts with standard donor hearts.
- Evaluation of mortality, infection, acute rejection, and right heart insufficiency.
Main Results:
- 1-year survival rate was 100% for both marginal and standard donor groups.
- Marginal donor group experienced significantly more early complications (83% vs. 13%).
- Post-ICU stay was longer for marginal donor recipients (35.5 days vs. 21.7 days).
Conclusions:
- Marginal donor hearts can increase transplant accessibility and benefit more patients.
- Increased risk of early complications necessitates careful patient selection.
- Close perioperative management is crucial for recipients of marginal donor hearts.
Background:
Although heart transplantation has become a standard therapy for end-stage heart disease, there are few published studies regarding the use of transplant organs from marginal donors. Here we describe the clinical outcome we have obtained using marginal donor hearts.
Methods:
We analyzed 21 cases of orthotopic heart transplantation for end-stage heart disease performed in our department between September 2008 and July 2010. Of these patients, six received hearts from marginal donors and the remainder received standard-donor hearts. The two groups were compared in terms of both mortality and the incidence of perioperative complications such as infection, acute rejection, and right heart insufficiency.
Results:
The 1-year survival rate of both groups was 100%. Only one death was recorded in standard-donor group during follow-up. Patients who received marginal donor hearts (83%) experienced more early complications than did the standard-donor-heart group (13%), but the mortality of the two groups was the same. The duration of post-ICU stay was greater in the marginal donor group than in the standard-donor group, (35.5 ± 17.4) days and (21.7 ± 2.6) days, respectively (P < 0.05).
Conclusions:
The use of marginal donor hearts increases the number of patients who can receive and benefit from transplants. However, it may introduce an increased risk of early complications, thus care should be taken both in the choice of patients who will receive marginal donor hearts and in the perioperative treatment of those for whom the procedure is performed.
